Compare Stocks

→ Will this $2 AI stock double overnight? (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKLI Akili	$0.25 +4.2%	$0.28	$0.19 ▼ $1.67	$19.49M	1.99	1.93 million shs	144,767 shs
LUCD Lucid Diagnostics	$0.68 -5.5%	$1.06	$0.67 ▼ $1.85	$34.88M	1.63	231,856 shs	234,871 shs
PLSE Pulse Biosciences	$6.86	$8.82	$3.78 ▼ $13.62	$378.85M	1.67	190,153 shs	129,153 shs

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKLI Akili	+3.77%	+16.32%	-15.62%	-2.78%	-76.38%
LUCD Lucid Diagnostics	-5.52%	-14.84%	-35.56%	-52.23%	-53.84%
PLSE Pulse Biosciences	0.00%	-8.17%	-19.67%	-18.72%	+17.26%

Will this $2 AI stock double overnight? (Ad)

It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!

Click here to learn more >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKLI Akili	2.9626 of 5 stars	3.5	5.0	0.0	0.0	1.1	1.7	1.3
LUCD Lucid Diagnostics	1.3526 of 5 stars	3.5	3.0	0.0	0.0	0.8	1.7	0.0
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKLI Akili	3.00	Buy	$4.00	1,512.90% Upside
LUCD Lucid Diagnostics	3.00	Buy	$2.75	302.58% Upside
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest PLSE, LUCD, and AKLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/12/2024	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.50
3/27/2024	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$3.80 ➝ $3.00
3/27/2024	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.50

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKLI Akili	$1.68M	11.60	N/A	N/A	$0.75 per share	0.33
LUCD Lucid Diagnostics	$2.43M	13.56	N/A	N/A	($0.47) per share	-1.45
PLSE Pulse Biosciences	$700K	541.16	N/A	N/A	$0.81 per share	8.47

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKLI Akili	-$59.49M	-$0.76	N/A	N/A	N/A	-3,545.47%	-76.34%	-56.48%	5/10/2024 (Estimated)
LUCD Lucid Diagnostics	-$52.67M	-$1.27	N/A	∞	N/A	-2,169.07%	-901.79%	-121.11%	5/20/2024 (Estimated)
PLSE Pulse Biosciences	-$42.21M	-$0.89	N/A	∞	N/A	N/A	-112.74%	-61.09%	5/9/2024 (Estimated)

Latest PLSE, LUCD, and AKLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/28/2024	Q4 2023	PLSE Pulse Biosciences	N/A	-$0.21	-$0.21	-$0.20	N/A	N/A
3/26/2024	Q4 2023	LUCD Lucid Diagnostics	N/A	-$0.26	-$0.26	-$0.26	N/A	$1.04 million
2/29/2024	Q4 2023	AKLI Akili	-$0.26	-$0.14	+$0.12	-$0.14	$1.07 million	$0.75 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKLI Akili	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
PLSE Pulse Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKLI Akili	0.09	6.02	6.02
LUCD Lucid Diagnostics	N/A	0.75	0.74
PLSE Pulse Biosciences	N/A	6.76	6.76

Ownership

Institutional Ownership

Company	Institutional Ownership
AKLI Akili	53.12%
LUCD Lucid Diagnostics	74.01%
PLSE Pulse Biosciences	76.95%

Insider Ownership

Company	Insider Ownership
AKLI Akili	10.10%
LUCD Lucid Diagnostics	4.80%
PLSE Pulse Biosciences	69.70%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
AKLI Akili	68	78.60 million	70.66 million	Optionable
LUCD Lucid Diagnostics	70	48.24 million	45.93 million	No Data
PLSE Pulse Biosciences	61	55.22 million	16.73 million	Optionable

PLSE, LUCD, and AKLI Headlines

Source	Headline
	Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024 businesswire.com - April 24 at 4:05 PM
	Pulse Biosciences to raise $60M massdevice.com - March 29 at 10:48 AM
	Q4 2023 Pulse Biosciences Inc Earnings Call finance.yahoo.com - March 29 at 10:48 AM
	PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023 investorplace.com - March 28 at 11:31 PM
	Pulse Biosciences Inc (PLSE) Reports Increased GAAP Costs and Narrowed Net Loss in 2023 finance.yahoo.com - March 28 at 7:45 PM
	Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results businesswire.com - March 28 at 4:12 PM
	Pulse Biosciences Announces Plans to Initiate a Rights Offering businesswire.com - March 28 at 4:10 PM
	PLSE Apr 2024 25.000 call finance.yahoo.com - March 17 at 10:01 AM
	PLSE Oct 2024 17.500 call finance.yahoo.com - March 17 at 12:13 AM
	PLSE Oct 2024 12.500 call finance.yahoo.com - March 16 at 2:13 PM
	PLSE Jul 2024 2.500 put finance.yahoo.com - March 16 at 2:13 PM
	Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024 businesswire.com - March 14 at 4:05 PM
	Pulse Biosciences’s CellFXnsPFA system secures FDA 510(k) clearance msn.com - March 13 at 7:07 PM
	FDA clears pulsed field ablation electrode tech from Pulse Biosciences massdevice.com - March 11 at 1:28 PM
	What to know about low blood pressure with a high pulse medicalnewstoday.com - March 10 at 2:46 PM
	FDA clears Pulse Biosciences' soft tissue ablation system investing.com - March 10 at 2:46 PM
	Pulse Biosciences Gets FDA 510(k) Clearance For CellFX NsPFA Percutaneous Electrode System markets.businessinsider.com - March 9 at 1:21 AM
	Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA(TM) Percutaneous Electrode System stockhouse.com - March 8 at 3:19 PM
	Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System businesswire.com - March 8 at 1:17 PM
	Pulse Biosciences reports positive 60-day evaluations for AFib-treating pulsed field ablation massdevice.com - February 14 at 12:51 PM
	Pulse Biosciences Announces Positive Results For CellFX NsPFA 360 Cardiac Catheter Study; Stock Up markets.businessinsider.com - February 14 at 12:51 PM
	Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study finance.yahoo.com - February 14 at 12:51 PM
	Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study businesswire.com - February 14 at 8:00 AM
	Companies Like Pulse Biosciences (NASDAQ:PLSE) Are In A Position To Invest In Growth finance.yahoo.com - February 2 at 12:21 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akili

NASDAQ:AKLI

Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.

Lucid Diagnostics

NASDAQ:LUCD

Lucid Diagnostics Inc., a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Pulse Biosciences

NASDAQ:PLSE

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial